secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001615219-25-000080
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharma expects Q2 net loss ~$900K, cash $800K; raises $3.8M via equity line
--------------------------------------------------------------------------------

- Preliminary Q2 2025 net loss ~$900,000; cash at June 30 was $800,000.
- Issued 5.5M shares under equity line for ~$3.8M gross proceeds post-quarter.
- As of July 30, 2025, pro forma cash ~$4.5M after issuance.
- Unregistered sale to C/M Capital Master Fund LP under purchase agreement.
- Preliminary results are subject to adjustment; not yet audited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000080/0001615219-25-000080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000080/flks-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer